Kelly Larkin, MD
Ophthalmology · Bellaire, TXNPI 1497040471
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 73.0% of it on its own, with 19 other manufacturers making up the rest. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $286.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$28K
- Regeneron$7K
- ANI Pharmaceuticals, Inc.$2K
- Sun Pharmaceutical Industries Inc.$377
- AbbVie$271
- Eyepoint US, Inc.$158
- plus $775 from 14 others
Across 31 payments — averaging $14,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$309K
- Eyepoint US, Inc.$107K
- Oyster Point Pharma, Inc.$32K
What the payments were for
- Consulting fees$14,44338%
- Speaking & faculty fees$19,66352%
- Travel & lodging$1,3504%
- Food & beverage$2,3636%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 57 | $27,605 |
| Regeneron | 4 | $6,580 |
| ANI Pharmaceuticals, Inc. | 3 | $2,070 |
| Sun Pharmaceutical Industries Inc. | 21 | $377 |
| AbbVie(2 entities) | 13 | $271 |
| Eyepoint US, Inc. | 5 | $158 |
| Bausch & Lomb Americas Inc. | 7 | $154 |
| Alimera Sciences, Inc. | 5 | $123 |
| Astellas Pharma US Inc | 1 | $122 |
| Alcon | 3 | $66 |
| Apellis Pharmaceuticals, Inc. | 3 | $59 |
| Portola Pharmaceuticals, LLC | 1 | $51 |
| Oyster Point Pharma, Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,836 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TepezzaTeprotumumab-Trbw | 12 | $679,892 |
| Humira(Cf) PenAdalimumab | 75 | $678,978 |
| RestasisCyclosporine | 41 | $33,096 |
| Difluprednate | 307 | $29,882 |
| ProlensaBromfenac Sodium | 75 | $26,906 |
| Bromfenac Sodium | 147 | $22,013 |
| CequaCyclosporine | 15 | $16,384 |
| XiidraLifitegrast | 17 | $15,443 |
| MieboPerfluorohexyloctane/Pf | 16 | $11,868 |
| Prednisolone Acetate | 214 | $9,936 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $7,952 |
| Cyclosporine | 12 | $7,478 |
| DurezolDifluprednate | 16 | $4,537 |
| ValacyclovirValacyclovir Hcl | 81 | $4,107 |
| Mycophenolate Mofetil | 35 | $3,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTepezza | $27,605 | $679,89212 claims |
| AbbVieRestasis, Combigan | $271 | $41,04759 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $154 | $27,31233 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $18 | $26,90675 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $377 | $16,38415 claims |
| NovartisDurezol | $24 | $4,53716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Bellaire
- Charles WykoffBellaire$1.5M
- Otis WaltonBellaire$311K
- Richard YeeBellaire$195K
- Prethy RaoBellaire$85K
- Hasenin Al-KhersanBellaire$76K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.